Literature DB >> 15934837

CDP-870 (certolizumab) in rheumatoid arthritis.

V V Kaushik1, R J Moots.   

Abstract

The development of biological anti-TNF-alpha therapy has revolutionised the treatment of rheumatoid arthritis and other inflammatory diseases, and has identified a worldwide market for expensive yet effective therapies for chronic diseases. Certolizumab (CDP-870) is a new agent that employs a novel strategy to neutralise TNF-alpha--namely the prokaryotic expression of TNF-alpha-specific Fab antibody fragments, coupled to polyethylene glycol--to produce a drug that is potentially less expensive to manufacture than other anti-TNF-alpha agents and which may be administered by subcutaneous injection once a month. The background to the ongoing development of this new agent and its clinical effects are discussed in this article.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15934837     DOI： 10.1517/14712598.5.4.601

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN： 1471-2598            Impact factor:   4.388


  13 in total

Review 1.  Pharmacogenetics of etanercept in rheumatoid arthritis.

Authors:  Maria I Danila; Laura B Hughes; S Louis Bridges
Journal:  Pharmacogenomics       Date:  2008-08       Impact factor: 2.533

Review 2.  TNFalpha blockade in human diseases: mechanisms and future directions.

Authors:  Maida Wong; David Ziring; Yael Korin; Sheetal Desai; Sungjin Kim; Jan Lin; David Gjertson; Jonathan Braun; Elaine Reed; Ram Raj Singh
Journal:  Clin Immunol       Date:  2007-10-03       Impact factor: 3.969

Review 3.  scFv antibody: principles and clinical application.

Authors:  Zuhaida Asra Ahmad; Swee Keong Yeap; Abdul Manaf Ali; Wan Yong Ho; Noorjahan Banu Mohamed Alitheen; Muhajir Hamid
Journal:  Clin Dev Immunol       Date:  2012-03-15

Review 4.  Certolizumab in the long-term treatment of rheumatoid arthritis.

Authors:  Abdul Khan; David L Scott
Journal:  Open Access Rheumatol       Date:  2011-08-25

5.  IL-32θ gene expression in acute myeloid leukemia suppresses TNF-α production.

Authors:  Man Sub Kim; Jeong-Woo Kang; Jae-Sik Jeon; Jae Kyung Kim; Jong Wan Kim; Jintae Hong; Do-Young Yoon
Journal:  Oncotarget       Date:  2015-12-01

Review 6.  Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies.

Authors:  G Malviya; F Conti; M Chianelli; F Scopinaro; R A Dierckx; A Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-24       Impact factor: 9.236

Review 7.  The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions.

Authors:  Shahin Shams; Joseph M Martinez; John R D Dawson; Juan Flores; Marina Gabriel; Gustavo Garcia; Amanda Guevara; Kaitlin Murray; Noah Pacifici; Maxemiliano V Vargas; Taylor Voelker; Johannes W Hell; Judith F Ashouri
Journal:  Front Pharmacol       Date:  2021-05-28       Impact factor: 5.810

Review 8.  TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease.

Authors:  Melissa K McCoy; Malú G Tansey
Journal:  J Neuroinflammation       Date:  2008-10-17       Impact factor: 8.322

Review 9.  Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol.

Authors:  Theresa Barnes; Robert Moots
Journal:  Int J Nanomedicine       Date:  2007

10.  Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.

Authors:  Yoshiya Tanaka; Kazuhiko Yamamoto; Tsutomu Takeuchi; Hisashi Yamanaka; Naoki Ishiguro; Katsumi Eguchi; Akira Watanabe; Hideki Origasa; Toshiharu Shoji; Nobuyuki Miyasaka; Takao Koike
Journal:  Mod Rheumatol       Date:  2014-03-04       Impact factor: 3.023
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.